Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies.
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab285
Abstract: OBJECTIVE To further characterize the effect of guselkumab, a selective interleukin-23p19-subunit inhibitor approved for psoriatic arthritis (PsA), on enthesitis and assess relationships between enthesitis resolution and patient status/outcomes. METHODS Adults with active PsA despite standard… read more here.
Keywords: psoriatic arthritis; resolution; enthesitis; disease ... See more keywords